InvestorsObserver
×
News Home

Should Biotechnology Stock X4 Pharmaceuticals Inc (XFOR) Be in Your Portfolio Monday?

Monday, April 01, 2024 01:42 PM | InvestorsObserver Analysts

Mentioned in this article

Should Biotechnology Stock X4 Pharmaceuticals Inc (XFOR) Be in Your Portfolio Monday?

X4 Pharmaceuticals Inc (XFOR) is near the top in its industry group according to InvestorsObserver. XFOR gets an overall rating of 72. That means it scores higher than 72 percent of stocks. X4 Pharmaceuticals Inc gets a 84 rank in the Biotechnology industry. Biotechnology is number 18 out of 148 industries.

Overall Score - 72
XFOR has an Overall Score of 72. Find out what this means to you and get the rest of the rankings on XFOR!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With X4 Pharmaceuticals Inc Stock Today?

X4 Pharmaceuticals Inc (XFOR) stock is trading at $1.38 as of 1:39 PM on Monday, Apr 1, a decline of -$0.01, or -1.08% from the previous closing price of $1.39. The stock has traded between $1.33 and $1.49 so far today. Volume today is below average. So far 1,522,412 shares have traded compared to average volume of 2,800,084 shares. Click Here to get the full Stock Report for X4 Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App